Pluristem moves to new GMP facility for PLacental eXpanded cell production

The company leverages 3D bioreactor technology in the production of the PLX cells to tackle issues such as reproducibility, production costs and quality.

Pluristem chairman and CEO Zami Aberman said the new manufacturing facility will allow the company to supply source in the placenta along with a proprietary expansion technology.

"Our new facility allows increasing the yield from one placenta to over ten times the yield from our previous pilot facility, and puts us in a very strong competitive position compared to traditional two-dimensional expansion technologies," Aberman added.

The new facility with a production capacity of more than 150,000 doses per year, is capable of producing different PLX product candidates in addition to supplying cells for required additional trials.